Totally agree $CDAK are around 18months further advanced in the development of Exosomes (delivery vehicle)

#RENE Mcap= £60m
$CDAK MCap= $591m

3 Companies evaluating RENE's platform

Currently snowed under with demand off other companies for Proof of Concept trials ImageImage

Are exosomes going to play a big role in future cell and gene delivery?


One of the brilliant things which Exosomes do is they have the ability to pass through the Blood Brain Barrier delivering signals and regulation into the Brain

This is extremely difficult to do and most drug delivery mechanisms fail to do this ImageImage

David Sinclair
A Professor in Genetics At Harvard Medical School
Who specialises in the Biology of Ageing explains

As we age “Sirtuins” which protect the body loose their ability to Silence (siRNA) Genes which should not be there

🚨He believes this is partly why we have Diseases of the Brain🚨

RENE have stayed in their recent Webinar exceptional demand from Top Cell and Gene Therapy players to partner with their Exosome platform, a platform that had already proven it can package siRNA and mRNA

The question is over the next 12 months HOW MANY Major Global Cell and Gene Therapy players will RENE develop partnerships with?

Exosome Collaboration Deals to date include

MAJOR Pharma
MAJOR Biotech

Including research grants from Innovative UK 🔥

Demand for their Exosome platform currently OUTSTRIPPING their functional capacity showing this delivery mechanism to potentially be breakthrough ImageImageImageImage

Update from the CEO regarding their Phase 2 trial in Retinitis pigmentosa (RP) an Eye Disease that causes blindness

Only Therapeutic currently on the market addresses 2% of the RP population

ReNeurons therapy shown to treat 100% of the population


A little understanding of Retinitis pigmentosa (RP) Image

Not only has RENE stem cell therapy
prevented continued deterioration
of vision it has
significant improved and restored vision on average by 8-10 letters
📈👁 Image

This is exciting as EYLEA 👁
(One of the best selling drugs in the world)🌍
Was approved on a visual acuity improvement of 9 Letters

In a different Eye Condition
(Wet AMD) ImageImageImage

ReNeuron aren’t stopping there

They have decided to DOUBLE the dose in a further Extension study to try to increase the efficacy even further 🔥

AIM: Letter Improvement increase from 8/10 Letters ➡️15+ Letters and it’s virtually near enough certain for approval 💥 Image

1st Patient in the increased dose cohort was reviewed by Data Safety Monitoring board

Allowing RENE to proceed to dose a further 2 patients before the next evaluation

This is an encouraging sign that there are no Serious Adverse Events relating to the increased dose

3/9 Patients have now been dosed and shortly we will receive a thorough Safety update of the expanded cohort which I anticipated to be good

This trial is open label (ReNeuron can see the safety and results as they go along)

Given the recent enthusiasm by both the CEO and the Principal Investigator validates the thesis that the expansion Cohort will be Safe

Potentially showing further improved GAME CHANGING results for this “innovative” Stem Cell Therapy💥 ImageImage

Validation of the HUGE promise of Exosomes

Highly educated individual with vast knowledge and experiance within Medical Research
Ex Chief Scientific Officer to $81.6Bn Gilead💥 ImageImage

Are Exosomes actually the key driver in treating disease

Understand the bodies deep mechanisms beyond cell therapy... ImageImageImageImage

Are Exosome infused miRNA the next generation Cell Therapies?


Are Exosomes the key drug delivery vehicle for fighting disease?


Exosome based CD24 molecule

It seems Exosomes are the KEY delivery capsule for cell to cell interaction🔑

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Hardy AIM 🎯

Hardy AIM 🎯 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AimHardy

11 Jan

Life expectancy over a 300 year time span

1800 to 2100

(IMO I believe millennials who looks after themself now will now live beyond 150 years old due to health care advancements over the following decades🤷🏼‍♂️)

Call me crazy 🤪
1800 to 1890

From 43yrs to 50yrs (16% incr)
1890 to 1980

HUGE jump

From 50yrs to 76yrs old (52% incr)
Read 7 tweets
9 Jan

I think the fact that MRx0518 is showing massive near term promise in cancer, yet 4D continue to focus on Parkinson's Disease shows me how excited and effective they believe MRx0029 may be for Parkinson's
(Market expected to reach $8.3bn by 2026)

medgadget.com/2020/02/parkin… Image

After discussing MRx0029 in the text, the author from 4D heavily alludes to bringing in a partner... Image

BOLD Statement

'MRx0029 has shown promise as a potentially
disease-modifying therapy, by indicating a potentially neuro-regenerative effect' Image
Read 6 tweets
26 Aug 20

Today 4D announce phenomenal trial results for the combination of @Merck's KEYTRUDA with MRx0518 in Lung and Kidney Cancer💥🚨

A staggering 42% achieved clinical benefit in a population that had exhausted all other methods of disease/cancer treatment

For a population which has been resistant to all other lines of therapies, this is hugely encouraging... if they can treat the most resistant...
...cancers in terminally ill patients, this bodes EXTREMELY well for earlier lines of therapy😬

Also, as the patient population has no other effective treatment this significantly increases the chances of early approval off the back of Phase 2 data
Potentially FDA...
Read 10 tweets
23 Jul 20

Why I believe @4dpharmaplc are on the cusp of a multi hundred million pound licencing deal for IBD and IBS?


Great Video 'Our Approach' highlighting @4dpharmaplc world leading innovative concept

Harnessing the bodies own Microbiome (Gut Bacteria) to solve genetic imbalances and malfunctions commonly referred to as diseases


Are you excited yet?

Read 96 tweets
23 Jul 20

Why I believe @4dpharmaplc are on the cusp of a multi hundred million pound licencing deal for IBD and IBS?

Phase 1 data for @4dpharmaplc Blautix's treatment of IBS highlights significant efficacy

-82% Improvement in a reduction of symptoms
-More diverse stable gut bacteria

4dpharmaplc.com/application/fi… ImageImage

Interim Safety Data for Blautix Phase 2 larger study shows excellent safety profile

-Comparable to placebo

We are awaiting efficacy data from the Phase 2 study anticipated this Quarter

4dpharmaplc.com/en/newsroom/pr… Image
Read 5 tweets
16 Jul 20

MaxCyte is a cell engineering platform, which uses non viral mRNA for drug development in a wide range of diseases including
-Auto Immune Diseases

11 Commercial Licencing deals with over
-$800m in Milestone Payments Image

MaxCyte is based on their patented novel drug development approach which is Flow Electroporation

Flow Electroporation is reprogramming of Human T-Cells

What this means is they have a machine that can modify any human/patients cells in order to target a specific problem Image

This as I hope you will understand offers enormous potential to address a wide range of therapeutic issues all under the platform which they own
Read 31 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!